Share your research at the 2026 Spring Scientific, Next-generation Cellular Therapies, T cell Engagers, and Combinations. Submissions close on Jan. 15, 2026. Don’t miss the opportunity to submit your Abstract. Learn more: https://sitcancer.org/edu/2026-spring-scientific

New Journal for ImmunoTherapy of Cancer article: In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses t.co/MH5lQvHMLw 🧪 #JITC #MedSky #ImmunoSky

This holiday season, the SITC family celebrates you. As we turn the page on a year of uncertainty, we thank the cancer immunotherapy professionals whose tireless work continues to bring hope, advance science, and transform lives. #Immunotherapy https://www.sitcancer.org/about/mission#sitc-timeline

We are proud to support global scientific exchange! Join leading scientists at the 18th #Breast Gynecological International #Cancer Conference Jan. 22-23 in Cairo, Egypt. View cutting-edge presentations advancing breast and #gynecologic cancer #research. Learn more: https://ow.ly/nAEU50XLtUH

Early registration for our Winter School Program closes tomorrow. Register to understand the fundamentals of how the immune system enables #cancer #immunotherapy. Held in Boston, MA or virtually: sitcancer.org/edu/winterschool#cancer#immunotherapy

In the December #JITC Digest, Editor-in-Chief Dr. Michael Lotze highlights the latest developments and emerging trends in cancer immunotherapy. This month's selection of manuscripts features a fundamental focus on mechanisms of IO involving Tregs. Read the Dec. Issue: https://ow.ly/mwub50XL4o4#JITC

SITC is proud to support OVAC & today’s Day of Action. Together, we can drive progress in cancer research, prevention, and care. We urge Congress to prioritize increased federal funding for #CancerResearch & #CancerPrevention programs.

Cancer remains the nation’s #2 killer—that’s why Society for Immunotherapy of Cancer#2joins OVAC & fellow members in urging Congress to make vital investments in #CancerResearch & #CancerPrevention: $47.2B for the NIH $7.374B for the NCI $1.5B for ARPA_H $417.5M for the CDC #FY26

Today, Society for Immunotherapy of Cancer joins One Voice Against Cancer's (OVAC) Day of Action, urging Congress to pass a full-year funding bill & prioritize funding for the NCI, NIH & CDC for #FY26! We can’t afford to pause progress on cancer research & prevention funding. #CancerVoice25

Out now: We present antibody-lectin chimeras (AbLecs) as a molecular platform to target sugars, or glycans, for cancer immunotherapy. www.nature.com/articles/s41... www.nature.com/articles/s41... @mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social

Dr. Stark, thank you for acknowledging SITC's support! We are pleased to see your recent work on antibody-lectin chimeras published and appreciate your contributions to advancing this critical area of research.

New Journal for ImmoTherapy of Cancer article: Colorectal cancer organoids drive hypoxia, TGF-β, and patient-specific diversification of NK cell activation programs t.co/QTd6A59Ul5 #JITC #ImmunoSky

Call for Comment: SITC invites public review of the new draft clinical practice guideline on immunotherapy for the treatment of multiple myeloma v2.0. Deadline to submit a request is December 22nd. More at: https://ow.ly/BYii50XIBcP #MultipleMyeloma #Cancer #SITCGuidelines

Now is the time to receive MOC Credits before the end of the year! Earn the SITC Certificate in #Cancer #Immunotherapy to support your knowledge and skills to provide effective and safe care for patients treated with cancer immunotherapy. Register at: https://www.sitcancer.org/certificate

Jean-Philippe Spano presents, "Survival outcomes in POD1UM-303/InterAACT-2: A phase III study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC)” at #ESMOImmuno25.

As Fangling Ning presents data on SIRpα-fc fusion protein at #ESMOImmuno25, address blockade of CD47 with this recent #JITC article from Chilam Chan et al of UMC Utrecht: https://ow.ly/lbJV50XH7A5

#ICYMI: At #ESMOImmuno25, Antonia Busse presented, “A phase I trial of IMA203CD8, a PRAME-directed TCR T cell therapy in PRAME-positive solid tumors”.

At #ESMOImmuno25, Hans Nijman reports how “Neoadjuvant immune checkpoint inhibition skews the B cell response in mismatch repair deficient endometrial cancer”.

As Dimitrios A. Garyfallos shares new findings on, “In vivo CRISPR/Cas9 genetic screens identify novel immunotherapy target” at #ESMOImmuno25, discover more on CRISPR with #JITC!

Exciting science unfolding at #ESMOImmuno25! Today’s oral abstract session featured Andreas Pircher’s presentation on, “Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME)."

Calling IO researchers with interests in cellular therapy, T cell engagers, and immuno-oncology drug development. The 2026 Spring Scientific is the program for you. Early registration rates end Jan. 9, 2026. Register here: https://sitcancer.org/edu/2026-spring-scientific

While at #ASH25, visit SITC in booth 2014 and learn how a membership provides exclusive tools, education and leadership opportunities to progress your career. #SITC #Immunotherapy

Register today to attend the #SITC Winter School Program! This hybrid program provides the best in cancer immunotherapy education taught by leading experts in the field. Held Feb. 16-18, 2026, in Boston, MA, or virtually. sitcancer.org/edu/winterschool#SITC

Are you at #ASH25? Visit SITC booth 2014 to learn more about an upcoming free Dec. 17 webinar, Bispecifics and T cell Engagers: Practical Strategies for Recognizing and Managing Toxicities.

Heading to #ASH25? Don’t miss your chance to visit SITC at booth 2014! Learn how SITC’s Advances in Cancer Immunotherapy™ program can help you stay at the forefront of immunotherapy education whether you’re new to the field or looking to deepen your expertise.

Working in Cancer IO? Visit SITC at #ASH25 booth 2014 and learn about the only member-driven society dedicated to cancer immunotherapy research and application. Find out about: ACIs, Cancer Immunotherapy Winter School, JITC, the Spring Scientific, and more!

New Journal for ImmunoTherapy of Cancer article: Neutrophil extracellular traps–STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer jitc.bmj.com/content/13/1... #JITC #MedSky

Today is Giving Tuesday! Be sure to grab your SITC merchandise or make a donation to the Forward Fund. With your support we can continue to fund the research of promising scientists in the field of cancer immunotherapy! https://www.sitcancer.org/get-involved/support

Dr. Natri, we’re excited to welcome you to the Sparkathon class of 2026! We can’t wait to see you in Tucson.

New Journal for ImmunoTherapy of Cancer article: Engineering TME-activated CD47-specific CAR macrophage via Arg1 promoter for safe and effective solid tumor immunotherapy t.co/xYSEvcRGST #JITC #ImmunoSky

Discover novel IO targets and biotherapeutics! Attend tomorrow's AI, Upcoming Technologies, and Potential Applications #webinar to gain valuable insights for predicting patient responses to immunotherapy. Learn more and register: https://ow.ly/R6Uq50XA2uX

Stay in the know with #SITC! Explore our upcoming events, webinars, and important dates by looking at our calendar. Learn More: https://sitcancer.org/get-involved/events/calendar#SITC#Immunotherapy

See what is new with SITC by checking out the November edition of the SITC Immune Monitor. Learn about upcoming programs and the most recent society news. Read more here: https://www.sitcancer.org/blogs/sitc-communications/2025/11/25/immune-monitor-november-2025

Registration is open for Next-generation Cellular Therapies, T cell Engagers, and Combinations. Happening March 25–27 in Tucson, AZ or virtual. Join experts in cell therapy, drug development, and IO at Spring Scientific. Register here: https://sitcancer.org/edu/2026-spring-scientific

Bispecifics and T cell engagers are transforming care for hematologic malignancies and solid tumors! Join our free webinar Dec. 17 to gain practical strategies for managing toxicities from these modalities and improve patient care. View more: https://ow.ly/gUIq50XwRuI

We are excited to announce the SITC Spring Scientific keynote speaker will be Dr. Kristen M. Hege. Join experts in cell therapy, drug development, and IO at Spring Scientific. Register here: https://sitcancer.org/edu/2026-spring-scientific

Four weeks left before early registration to the #SITC Winter School Program closes. Do not miss the opportunity to attend this program! Held Feb. 16-18, 2026, in Boston, MA, or virtually. Check out the schedule and registration rates: sitcancer.org/edu/winterschool#SITC

Neoadjuvant therapy and more! Understand fundamental IO concepts with our joint Primer with ESMO - European Society for Medical Oncology. Join SITC speakers Dec. 10 at the 2025 ESMO Immuno-Oncology Congress in London, UK: https://ow.ly/NFuI50XuKFN Daniela Thommen Netherlands Cancer Institute

What a fantastic opportunity to share our work! Thank you organizers for a great pre-conference event at #SITC25 Looking forward to even more awesome science in the days to come!

Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏. This technology will expand access to solid tumor cell therapy 🌟

Our #SITC25 recap is out today! Check out the standout presentations and insights from top institutions and speakers: bit.ly/3LLunuM#SITC25

The Certificate in Cancer Immunotherapy by SITC is a great way to gain knowledge in the #IO field. By completing eight expert led modules, you can receive CME, CNE, CPE or MOC credit. Consider registering today to enhance your skills. https://www.sitcancer.org/certificate#IO#IOcertificate

In the Nov. Issue of the #JITC Digest, Editor-in-Chief Dr. Michael T. Lotze reflects on his experience at #SITC25 and several recent IO meetings. Explore his curated selection of cutting-edge articles, including new insights on LAG-3 blockade and more. View the Nov. Issue: https://ow.ly/fTO150Xun1R#JITC

Tomorrow is the deadline to apply for the SITC Sparkathon class of 2026. Qualified scientists will meet on March 23–25, 2026, in Tucson, AZ. #immunotherapy #cancer #ECR. Apply by Nov. 19: https://www.sitcancer.org/sparkathon#immunotherapy#cancer#ECR#ECR

New Journal for ImmunoTherapy of Cancer review: Myeloid metabolism and its role in immunotherapy of cancer jitc.bmj.com/content/13/1... #JITC #MedSky 🧪

One week left to apply for the SITC Sparkathon class of 2026. Qualified scientists will meet on March 23–25, 2026, in Tucson, AZ. #immunotherapy #cancer #ECR. Apply by Nov. 19: https://www.sitcancer.org/sparkathon#immunotherapy#cancer#ECR#ECR

Join us for tomorrow's #comp #IO webinar: Using Spatial Biology to Monitor Tumor Immune Interactions. Review methods for extracting information on the tumor immune microenvironment from spatial imaging and spatial genomics assays! Register: https://www.sitcancer.org/edu/webinars/computational#comp

Abstract submissions for Spring Scientific are open through Jan. 15, 2026. Don’t miss this opportunity to share your research with your colleagues and fellow immuno-oncology professionals. Learn more about the program and register: https://sitcancer.org/edu/2026-spring-scientific

New Journal for ImmunoTherapy of Cancer review: Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions jitc.bmj.com/content/13/1... #JITC #ImmunoSky 🧪

We had a very productive week at the 40th @sitcancer.bsky.social 2025 meeting. Learned a lot from experts sharing cutting-edge research in immunotherapy, and loved to see my team engaging with attendees from all over the globe. #AntunesLab @uh.edu